Bio-Techne Corp

TECH is stalled near multi-month highs at the historical resistance zone around $72, with converging EMAs tracking underneath. Long- and medium-term biases remain bullish based on a rising long-term trend and Stage 2 advance, but an active bullish exhaustion pattern highlights weakening upside momentum and leaves no clear short-term entry. Execution is best deferred until a decisive breakout above resistance or a pullback into rising EMAs.

• ↑Q1 2027 revenue of $79.1M and GPU cloud ARR ~$110M show robust demand.
• ↑Earnings yield ~29% indicates attractive valuation for investors.
• ↓Negative growth factors signal potential stagnation in revenue expansion.